



#### Is Medical Evidence Enough?

#### How Evidence Based Medicine Affects Family Planning Providers: A Randomized Experiment in Jordan

**Presenter:** Marianne El-Khoury

Authors: Rebecca Thornton (University of Michigan), Marianne El-Khoury, Minki Chatterji, Maha Shadid, and Soonie Choi (Abt Associates)

13 April 2013



SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes International Monitor Group O'Hanlon Health Consulting

# Background


- Biases and misconceptions held by health providers can adversely affect the delivery of quality health services.
- In Jordan, misconceptions toward family planning methods, especially hormone-based are common.
- Some studies find that using Evidence Based Medicine (EBM) approach helps reduce biases among providers.
- Research evidence disseminated through professional courses, workshops, educational outreach visits, or similar interventions

## Objectives

- Study the impact of an EBM intervention in Jordan aimed to dispel misconceptions related to depot medroxy progesterone (DMPA), a 3-month hormonal injectable contraceptive on:
  - Providers' knowledge of DMPA and its side effects
  - Attitudes and perceived confidence towards DMPA
  - Clinical behaviors, such as discussion and prescription of DMPA

#### Methods

- Sample: 267 private health providers in two urban areas of Jordan, Amman and Zarqa
- Random assignment into Treatment (135) and Control (132), stratified by area and gender
- Baseline and endline surveys
- Overall response rates: 73% (baseline) and 85% (endline).



# **EBM DMPA Intervention**

#### Treatment

- Providers invited to attend a roundtable seminar discussing research evidence on DMPA
- Providers participate in two educational visits to reinforce seminar messages on DMPA

#### Control

 Providers participate in two repeat educational visits to reinforce prior seminar messages on Combined Oral Contraceptives (COC)

#### Provider Characteristics and Baseline Equivalence

|   | Treatment | Control | Diff  | (S.E.) |
|---|-----------|---------|-------|--------|
| <b>Provider Characteristics</b>                 |           |         |       |        |
| Female  | 0.68      | 0.69    | -0.01 | (0.06) |
| Yrs clinical experience                         | 24.60     | 24.80   | -0.20 | (1.07) |
| Yrs clinical experience in FP                   | 17.10     | 17.60   | -0.50 | (1.19) |
| Num patients per week                           | 83.40     | 90.20   | -6.80 | (9.48) |
| Num FP patients per week                        | 16.30     | 20.41   | -4.11 | (3.16) |
| <b>Baseline Knowledge/Attitudes/Practices</b>   |           |         |       |        |
| DMPA Knowledge Score (standardized)             | 0.08      | 0.03    | 0.05  | (0.16) |
| Positive Attitude Score (standardized)          | 0.00      | 0.01    | 0.00  | (0.15) |
| Availability of DMPA stock at clinic            | 0.20      | 0.23    | -0.03 | (0.06) |
| Times discussed DMPA with clients in past month | 4.91      | 5.84    | -0.93 | (1.18) |
| Times prescribed DMPA in past month             | 1.85      | 2.43    | -0.58 | (0.55) |

# **Estimation Strategy**

Intent to treat (ITT) estimates using OLS:

• 
$$Y_i = \alpha_1 + \beta_1 T_i + \varepsilon_{1i}$$
 Eq (1)

 Treatment on the treated (TOT) estimates using IV (2SLS):

• 
$$Y_i = \alpha_2 + \beta_2 A C \widehat{TUAL} T_i + \varepsilon_{2i}$$
 Eq (2)


Where first stage is:

•  $ACTUAL_T_i = \alpha_3 + \beta_3 T_i + \varepsilon_{3i}$  Eq (3)


## Adherence to Intervention

|   | Treatment<br>N=135 | Control<br>N=132 |  |
|---|--------------------|------------------|--|
| Attended EBM seminar  | 0.452              | 0.015            |  |
| Received both educational visits on DMPA                      | 0.763              | 0.000            |  |
| Received at least one educational visit on DMPA               | 0.852              | 0.000            |  |
| Attended seminar AND received both educational visits on DMPA | 0.385              | 0.000            |  |
| Received at least one educational visit on COC                | 0.000              | 0.848            |  |


## Impact on Knowledge




#### Impact on Attitudes



#### Impact on Perceived Confidence



#### **Impact on Clinical Practices**



Treatment on Treated (IV)
Intention to Treat (OLS)

# Summary / Discussion

• Overall, absence of large and significant impacts

- Some evidence of positive impact on willingness and comfort prescribing DMPA
- Providers less likely to identify two common and important side effects of DMPA
- Possible reasons:
  - High rate of no-shows to seminar; evidence of positive selection
  - Significant demand-side bias regarding DMPA
  - 'Light' intervention?
- Study limitations





#### Marianne El-Khoury Marianne\_ElKhoury@abtassoc.com

www.shopsproject.org



SHOPS is funded by the U.S. Agency for International Development. Abt Associates leads the project in collaboration with Banyan Global Jhpiego Marie Stopes International Monitor Group O'Hanlon Health Consulting

# Table A: Impact on Knowledge of DMPA

|  | Control group<br>variable mean |       | Coefficient estimate<br>on treatment<br>(OLS) |         | Coefficient estimate<br>on actual intervention<br>(IV-2SLS) |         |
|--|--------------------------------|-------|---|---------|---|---------|
|  | Mean                           | S.D.  | Mean  | S.E.    | Mean  | S.E.    |
| Dependent variable: Agree with -   |                                |       |   |         |   |         |
| "Women who use DMPA less likely to suffer from anemia"                           | 0.625                          | 0.486 | 0.101   | [0.062] | 0.233   | [0.143] |
| "Use of DMPA associated with weight gain"  | 0.384                          | 0.489 | -0.008  | [0.064] | -0.018  | [0.147] |
| "Women who use DMPA more likely to experience amenorrhea"                        | 0.848                          | 0.360 | -0.053  | [0.051] | -0.122  | [0.117] |
| "Women who use DMPA more likely to experience spotting"                          | 0.902                          | 0.299 | -0.081*                                       | [0.045] | -0.186*   | [0.108] |
| "I should not prescribe DMPA to nulliparous women who wish to delay childbirth"  | 0.563                          | 0.498 | 0.027   | [0.066] | 0.063   | [0.151] |
| "DMPA use is safe for most healthy women"  | 0.857                          | 0.351 | 0.049   | [0.043] | 0.112   | [0.097] |
| Dependent variable: Disagree with -  |                                |       |   |         |   |         |
| "Women are at a higher risk of ectopic pregnancy if they use DMPA long term"     | 0.839                          | 0.369 | 0.015   | [0.048] | 0.035   | [0.109] |
| "DMPA use is associated with an increased incidence of breast cancer"            | 0.759                          | 0.430 | 0.070   | [0.054] | 0.161   | [0.124] |
| "After two years of continuous use of DMPA, women should give their body a rest" | 0.259                          | 0.440 | 0.023   | [0.059] | 0.053   | [0.134] |
|  |                                |       |   |         |   |         |
| Knowledge score effect (standardized)  | 0.000                          | 1.000 | 0.061   | 0.129   | 0.141   | 0.294   |

# Table B: Impact on Attitudes andPerceived Confidence in DMPA

| Dependent variable   |       | l group<br>e mean | Coefficient estimate<br>on treatment<br>(OLS) |         | Coefficient estimate<br>on actual intervention<br>(IV-2SLS) |         |
|--|-------|-------------------|---|---------|---|---------|
|  | Mean  | S.D.              | Mean  | S.E.    | Mean  | S.E.    |
| Agree with: "For some women, amenorrhea can be beneficial or desired"  | 0.670 | 0.472             | -0.029  | [0.063] | -0.066  | [0.145] |
| Agree with: "I would like to obtain more DMPA info"  | 0.839 | 0.369             | -0.044  | [0.051] | -0.102  | [0.118] |
| Agree with: "If women in Jordan had more<br>information about DMPA, more women might<br>accept its use"      | 0.759 | 0.430             | 0.044   | [0.055] | 0.102   | [0.125] |
| Agree with: "I would have no hesitations to recommend DMPA to a healthy woman who wanted to use this method" | 0.830 | 0.377             | 0.076*  | [0.045] | 0.173*  | [0.103] |
| Attitude score effect (standardized)   | 0.000 | 1.000             | 0.046   | 0.131   | 0.106   | 0.297   |
|  |       |                   |   |         |   |         |
| Feel knowledgeable about DMPA [0-10]   | 7.866 | 1.882             | 0.202   | [0.260] | 0.464   | [0.589] |
| Feel confident discussing DMPA [0-10]  | 7.793 | 2.534             | 0.147   | [0.340] | 0.338   | [0.775] |
| Feel comfortable prescribing DMPA [0-10]   | 5.955 | 3.198             | 0.917**                                       | [0.424] | 2.103**   | [0.990] |
| Perceived Confidence Score effect (standardized)   | 0.000 | 1.000             | 0.188   | 0.137   | 0.464   | 0.589   |

## **Table C: Impact on Reported Practices**

| Dependent variable  | Control group<br>variable mean |       | Coefficient<br>estimate on<br>treatment<br>(OLS) |         | Coefficient<br>estimate on actual<br>intervention<br>(IV-2SLS) |         |
|---|--------------------------------|-------|--|---------|--|---------|
|   | Mean                           | S.D.  | Mean   | S.E.    | Mean   | S.E.    |
| Availability of DMPA stock at clinic                      | 0.268                          | 0.445 | -0.088   | [0.055] | -0.203   | [0.131] |
| Number of times discussed DMPA with clients in past month | 12.28                          | 57.53 | -3.67  | [5.71]  | -8.51  | [13.25] |
| Number of times prescribed DMPA in past month             | 2.80                           | 5.29  | 0.77   | [0.70]  | 1.78   | [1.63]  |

# Table D: Baseline Statistics, by Seminar Attendance

|   | Seminar = 1 | Seminar =0 | Difference (1) - (2) |          |
|---|-------------|------------|----------------------|----------|
|   |             | Semmar =0  | Mean                 | SE       |
|   | (1)         | (2)        | (3)                  |          |
| Baseline Knowledge on DMPA                                    |             |            |                      |          |
| Disagree: Higher risk of ectopic pregnancy                    | 0.729       | 0.750      | -0.021               | 0.073    |
| Disagree: Higher risk of breast cancer                        | 0.875       | 0.800      | 0.075                | 0.064    |
| Agree: Anemia less likely                                     | 0.771       | 0.607      | 0.164                | 0.079**  |
| Disagree: After two years DMPA, should give body rest         | 0.521       | 0.312      | 0.209                | 0.079*** |
| Agree: Weight gain more likely                                | 0.437       | 0.389      | 0.048                | 0.082    |
| Agree: Should not prescribe if nulliparous and wants to delay | 0.255       | 0.243      | 0.012                | 0.073    |
| Agree: Safe for most healthy women                            | 0.937       | 0.860      | 0.077                | 0.054    |
| Average Knowledge Score (normalized)                          | 0.289       | -0.032     | 0.321                | 0.167*   |
|   |             |            |                      |          |
| Baseline Attitudes  |             |            |                      |          |
| Agree: for some, amenorrhea can be beneficial                 | 0.812       | 0.657      | 0.155                | 0.076**  |
| Agree: If more had info, more might use DMPA                  | 0.704       | 0.746      | -0.042               | 0.077    |
| Agree: No hesitations to prescribe DMPA                       | 0.854       | 0.792      | 0.063                | 0.066    |
| Agree: I would like more info on DMPA                         | 0.959       | 0.914      | 0.045                | 0.043    |
| Average Positive Attitude Score (normalized)                  | 0.162       | -0.040     | 0.202                | 0.169    |
|   |             |            |                      |          |
| Baseline Practices  |             |            |                      |          |
| Availability of DMPA stock at clinic                          | 0.239       | 0.212      | 0.028                | 0.071    |
| Average # times discussed DMPA with clients in past month     | 5.200       | 5.482      | -0.282               | 1.270    |
| Average # times prescribed DMPA in past month                 | 1.950       | 2.270      | -0.320               | 0.612    |
| Sample (N)  | 63          | 204        |                      |          |